EIF2AK3 and neuroblastoma: As pERK inhibition was more potent in the trametinib-treated cells, we treated SHP099-insensitive NB cells (COG-N-415 and COG-N-496) and SHP099-sensitive NB cells (SK-N-FI and COG-N-561) with SHP099 or the distinct and more potent SHP2 inhibitor RMC-4550 (Nichols et al., 2018).